References
- Czuczman M, Porcu P, Johnson J, Niedzwiecki D, Kelly M, Hsi E, et al. Results of a phase II study of 506U78 in cutaneous T-cell lymphoma and peripheral T-cell lymphoma: CALGB 59901. J Leuk Lymphoma 2006; 48: 97–103
- Kurtzberg J, Ernst T J, Keating M J, Gandhi V, Hodge J P, Kisor D F, et al. Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies. J Clin Oncol 2005; 23: 3396–3403
- Kisor D F, Plunkett W, Kurtzberg J, Mitchell B, Hodge J P, Ernst T, et al. Pharmacokinetics of nelarabine and 9-Beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies. J Clin Oncol 2000; 18: 995–1003
- Berg S L, Blaney S M, Devidas M, Lampkin T A, Murgo A, Bernstein M, et al. Phase II Study of nelarabine (compound 506u78) in children and young adults with refractory t-cell malignancies: a report from the children's oncology group. J Clin Oncol 2005; 23: 3376–3382
- Gandhi V, Plunkett W, Rodriguez C O, Jr, Nowak B J, Du M, Ayres M, et al. Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response. J Clin Oncol 1998; 16: 3607–3615
- Giblett E, Ammann A, Wara D, Sandman R, Diamond L. Nucleoside-phosphorylase deficiency in a child with severely defective T-cell immunity and normal B-cell immunity. Lancet 1975; 1: 1010–1013
- Cohen A, Gudas L, Ammann A, et al. Deoxyguanosine triphosphate, a possible toxic metabolite in immunodeficiency associated with purine nuclotide phosphorylase deficiency. J Clin Invest 1978; 61: 1405–1410
- Gravatt L C, Chaffee S, Hebert M E, Halperin E C, Friedman H S, Kurtzberg J. Efficacy and toxicity of 9-Beta-D-arabinofuranosylguanine (araG) as an agent to purge malignant T cells from murine bone marrow: application to an in vivo T-leukemia model. Leukemia 1993; 7: 1261–1267
- Hebert M E, Greenberg M L, Chaffee S, Gravatt L, Hershfield M S, Elion G B, et al. Pharmacologic purging of malignant T cells from human bone marrow using 9-Beta-D-arabinofuranosylguanine. Transplantation 1991; 52: 634–640